.svg)
Coronary Artery Disease and the Blood Markers Behind Plaque
Coronary artery disease (CAD) biomarkers are blood signals that reveal what is happening inside the artery wall and heart muscle. They capture plaque build-up and particle burden (LDL cholesterol, apolipoprotein B), inherited plaque-accelerating particles (lipoprotein(a)), the “heat” of immune activation that makes plaques fragile (high-sensitivity C-reactive protein), the body’s clot-forming tendency (fibrinogen, platelet activation markers), metabolic stress that fuels plaque growth (insulin resistance, triglyceride-rich lipoproteins), and silent heart injury or strain (high-sensitivity troponin, natriuretic peptides). Together they translate an invisible process—atherosclerosis—into numbers you can track. Measuring them helps estimate personal risk, reveal hidden vulnerability even when you feel well, and prioritize the most effective prevention steps. They also guide treatment choices—how intensively to lower LDL particle load, whether to target inflammation or thrombosis—and show whether therapy is working over time. In short, CAD biomarkers let you see the biology behind future heart attacks before they strike, so care can be targeted, timely, and preventive.
Why Lipid and Inflammatory Markers Matter for Heart Risk
Blood tests for coronary artery disease (CAD) reveal how your lipids and immune system shape plaque growth, vessel inflammation, and oxygen delivery. They capture two forces: particles that carry cholesterol into artery walls and the inflammatory tone that makes plaques unstable—processes that affect the heart, brain, kidneys, and muscles long before symptoms.LDL and ApoB reflect the number of atherogenic particles; optimal values sit toward the low end. LDL is often considered desirable below 100, borderline 130–159, high 160+. ApoB commonly falls around 60–100, with lower generally better and higher risk above about 120. HDL helps remove cholesterol; higher tends to be protective, with 60+ favorable and low HDL more concerning (often <40 in men, <50 in women). Lp(a) is genetically set; below 30 is usual, 30–50 borderline, and 50+ high. hs-CRP tracks vascular inflammation; <1 is low risk, 1–3 average, >3 high. AIP (log triglycerides/HDL) signals small, dense LDL; <0.11 low risk, 0.11–0.24 intermediate, >0.24 high. NHR lacks standardized ranges, but lower is generally better.When these markers are low in the right places—LDL/ApoB, Lp(a), hs-CRP, AIP, NHR—arteries stay more elastic, plaques grow slowly, and symptoms may never appear. Very low HDL, by contrast, often reflects insulin resistance and higher triglycerides; men experience this more commonly. In women, CAD may present later and with atypical symptoms.Big picture: these biomarkers bridge liver metabolism, immune activation, and arterial biology. Tracking them refines long-term risk for heart attack, stroke, and peripheral artery disease and connects daily physiology to future cardiovascular resilience.
What a Cardiovascular Panel Can and Can't Settle
Coronary artery disease (CAD) blood testing provides a window into the health of your cardiovascular system, which is central to energy delivery, metabolism, brain function, and overall resilience. At Superpower, we measure key biomarkers—LDL, HDL, ApoB, Lp(a), hs-CRP, NHR, and AIP—to assess the balance between risk and protection in your arteries. These markers help us understand how well your body maintains the integrity of blood vessels, supports heart function, and manages inflammation, all of which are vital for long-term health.LDL (low-density lipoprotein) is often called “bad cholesterol” because it can deposit cholesterol in artery walls, contributing to plaque buildup. HDL (high-density lipoprotein), or “good cholesterol,” helps remove cholesterol from the bloodstream. ApoB (apolipoprotein B) reflects the number of particles carrying cholesterol that can enter artery walls, making it a direct measure of atherogenic risk. Lp(a) is a genetic variant of LDL that can further increase risk by promoting clot formation. hs-CRP (high-sensitivity C-reactive protein) is a marker of inflammation, signaling active processes that can destabilize plaques. NHR (non-HDL cholesterol to HDL ratio) and AIP (atherogenic index of plasma) integrate multiple lipid measures to provide a broader view of risk.Optimal levels of these biomarkers indicate stable vessel walls, efficient cholesterol transport, and low inflammation—conditions that support healthy blood flow and reduce the likelihood of artery narrowing or blockage. Imbalances can signal vulnerability to plaque formation, instability, or inflammation, all of which can compromise heart and systemic health.Interpretation of these biomarkers can be influenced by factors such as age, sex, pregnancy, acute illness, medications, and laboratory methods. These variables may shift results, so context is essential for accurate assessment.
FAQs
It’s a blood panel that maps the forces that form plaque in your heart arteries. Superpower tests LDL, HDL, ApoB, Lp(a), hs-CRP, and two composite indices—NHR and AIP. LDL and ApoB quantify the number of cholesterol-carrying particles that enter artery walls (atherogenic lipoproteins). HDL reflects reverse cholesterol transport. Lp(a) is an inherited particle that accelerates plaque and clotting risk. hs-CRP tracks background vascular inflammation. NHR (non–HDL-C to HDL-C ratio) and AIP (atherogenic index of plasma, derived from triglycerides and HDL-C) integrate lipid balance into risk signals.
Because plaque builds silently, this panel quantifies your upstream risk. ApoB and LDL show the concentration of artery-entering particles. Lp(a) reveals inherited, lifelong risk independent of LDL. hs-CRP shows whether vascular inflammation is amplifying plaque formation. HDL reflects reverse transport capacity. NHR and AIP combine lipid fractions to flag atherogenic patterns. Together, these results stratify your probability of coronary events and provide an objective baseline to track change over time.
Yes. With Superpower, our team member can organise a blood draw in your home. A licensed professional collects your sample, we process it with accredited labs, and results come with clear explanations and trend tracking.
Get a baseline at least once in adulthood. If results are low-risk and stable, repeat every 1–3 years. If values are high or you’re changing therapies, recheck in 6–12 weeks, then every 6–12 months once stable. Lp(a) is typically measured once (it’s genetic) unless major clinical changes occur. Testing frequency should reflect overall cardiovascular risk and the need to monitor change over time.
Recent infection, injury, surgery, or flare can raise hs-CRP and shift lipids. Nonfasting state and heavy alcohol intake raise triglycerides, affecting AIP and calculated LDL. Vigorous exercise, dehydration, pregnancy, menstrual phase, thyroid status, diabetes control, kidney or liver disease, and hormones (estrogen/testosterone) can change results. Medications such as statins, fibrates, niacin, steroids, and PCSK9 inhibitors alter lipid particles. Genetics strongly determines ApoB and especially Lp(a).
Fast 8–12 hours before testing triglycerides, AIP, and calculated LDL; water is fine. Avoid testing during acute illness and for 24 hours after strenuous exercise. Take routine medications unless your clinician advised otherwise. Arrive well-hydrated and rest seated 5–10 minutes before the draw. ApoB and Lp(a) don’t require fasting. Measure hs-CRP when you feel well to avoid infection-related spikes.
References
- Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., Watts, G. F., Borén, J., Fazio, S., Horton, J. D., Masana, L., Nicholls, S. J., Nordestgaard, B. G., van de Sluis, B., Taskinen, M. R., ... Catapano, A. L. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), 2459-2472. https://doi.org/10.1093/eurheartj/ehx144
- Sniderman, A. D., Thanassoulis, G., Glavinovic, T., Navar, A. M., Pencina, M., Catapano, A., & Ference, B. A. (2019). Apolipoprotein B particles and cardiovascular disease: A narrative review. JAMA Cardiology, 4(12), 1287-1295. https://doi.org/10.1001/jamacardio.2019.3780
- Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., McNeal, C. J., Moriarty, P. M., Natarajan, P., Nordestgaard, B. G., Parhofer, K. G., Virani, S. S., von Eckardstein, A., Watts, G. F., Stock, J. K., ... Catapano, A. L. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. European Heart Journal, 43(39), 3925-3946. https://doi.org/10.1093/eurheartj/ehac361
- Emerging Risk Factors Collaboration, Kaptoge, S., Di Angelantonio, E., Lowe, G., Pepys, M. B., Thompson, S. G., Collins, R., & Danesh, J. (2010). C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. The Lancet, 375(9709), 132-140. https://doi.org/10.1016/S0140-6736(09)61717-7
- Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Jr., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., Nordestgaard, B. G., Shepherd, J., & Willerson, J. T. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine, 359(21), 2195-2207. https://doi.org/10.1056/NEJMoa0807646
.avif)
.svg)
.svg)
